Biosynthetic Semaglutide's Real-World Effectiveness and Safety Profile Assessed in Type 2 Diabetes Patients
Comment on 'Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan'.
Abstract
A 30-week, multicentre, non-interventional study aimed to evaluate the real-world effectiveness, safety, and patient-reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes.